Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Czuba, Paweł" wg kryterium: Wszystkie pola


Wyświetlanie 1-4 z 4
Tytuł:
Dynamic force measurements of avidin-biotin and streptavdin-biotin interactions using AFM
Autorzy:
de Odrowąż Piramowicz, Marzena
Czuba, Paweł
Targosz, Marta
Burda, Kvĕtoslava
Szymoński, Marek
Powiązania:
https://bibliotekanauki.pl/articles/1041274.pdf
Data publikacji:
2006
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
atomic force microscopy
rupture force
loading rate
streptavidin
avidin
biotin
dissociation rate
Opis:
Using atomic force microscopy (AFM) we performed dynamic force measurements of the adhesive forces in two model systems: avidin-biotin and streptavidin-biotin. In our experiments we used glutaraldehyde for immobilization of (strept)avidin on the tip and biotin on the sample surface. Such interface layers are more rigid than those usually reported in the literature for AFM studies, when (strept)avidin is coupled with biotinylated bovine albumin and biotin with agarose polymers. We determined the dependence of the rupture forces of avidin-biotin and streptavidin-biotin bonds in the range 300-9600 pN/s. The slope of a semilogarithmic plot of this relation changes at about 1700 pN/s. The existence of two different regimes indicates the presence of two activation barriers of these complexes during the dissociation process. The dissociation rates and activation energy barriers, calculated from the Bell model, for the avidin-biotin and streptavidin-biotin interactions are similar to each other for loading rates >1700 pN/s but they are different from each other for loading rates < 1700 pN/s. In the latter case, the dissociation rates show a higher stability of the avidin-biotin complex than the streptavidin-biotin complex due to a larger outer activation barrier of 0.8 kBT. The bond-rupture force is about 20 pN higher for the avidin-biotin pair than for the streptavidin-biotin pair for loading rates < 1700 pN/s. These two experimental observations are in agreement with the known structural differences between the biotin binding pocket of avidin and of streptavidin.
Źródło:
Acta Biochimica Polonica; 2006, 53, 1; 93-100
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Effect of photodynamic therapy with hypericin on the secretion of selected cytokines of colorectal cancer cells tested in vitro
Autorzy:
Międzybrodzka, Anna
Kawczyk-Krupka, Aleksandra
Aebisher, David
Cieślar, Grzegorz
Czuba, Zenon Paweł
Powiązania:
https://bibliotekanauki.pl/articles/25102362.pdf
Data publikacji:
2023-06-30
Wydawca:
Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
Tematy:
colorectal cancer
hypericin
photodynamic therapy
Opis:
Introduction and aim. Photodynamic therapy is a complex process involving the introduction of photosensitizers into the patient’s body and irradiation of them in order to destroy the lesion, and activate the immune system. An important role in photodynamic therapy is played by photobiochemical and physical mechanisms that affect the tumor vessels and lead to the death of the damaged cell. The aim of the study is to determine the effect of photodynamic therapy with the use of Hypericin (Hyp) on the secretion of selected cytokines by colorectal cancer cells. Material and methods. Two colorectal cancer cell lines SW480 and SW620 were used in the study. Cells treated Hypericin were exposed to visible light. Then cell viability was determined by the MTT assay with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium. Assays were performed for control samples without hypericin and light exposure, with Hyp without light exposure, without Hyp and irradiated with light, and test samples with Hyp and light exposure. Results. In the experiment we reveal, that Hyp- photodynamic activity does not influence the secretion of cytokines. Conclusion. The obtaining results confirming the destructive effect of Hyp- PDT on the colon cancer cells, show a possibility of extending the indication for photodynamic therapy using Hyp, qualification of precancerous changes.
Źródło:
European Journal of Clinical and Experimental Medicine; 2023, 2; 194-201
2544-2406
2544-1361
Pojawia się w:
European Journal of Clinical and Experimental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Effects of hypericin-mediated photodynamic therapy on GM-CSF, MIF, VCAM-1 and ICAM-1 secretion in colorectal cancer cells in vitro
Autorzy:
Międzybrodzka, Anna
Kawczyk-Krupka, Aleksandra
Aebisher, David
Cieślar, Grzegorz
Czuba, Zenon Paweł
Powiązania:
https://bibliotekanauki.pl/articles/25102366.pdf
Data publikacji:
2023-06-30
Wydawca:
Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
Tematy:
colorectal cancer
hypericin
photodynamic therapy
Opis:
Introduction and aim. Photodynamic therapy with hypericin (HYP-PDT) is gaining importance as a potential treatment method for malignant neoplasms. The following study investigated whether HYP-PDT influences the secretion of certain factors of colon cancer cells in vitro. Material and methods. Two colon cancer cell lines were used in this experiment: SW480 and SW620. The cells were properly prepared and then treated with photodynamic therapy with hypericin at concentrations of 0.25 µM and 0.5 µM and irradiation at the doses of 1 J/cm2 , 5 J/cm2 and 10 J/cm2 . After using HYP-PDT, changes in the concentrations of four factors: GM-CSF, MIF, VCAM-1 and ICAM-1 were analyzed in the test tubes. Results. In the case of SW480 cells: a notable decrease in GM-CSF, MIF, VCAM-1 and ICAM-1 secretion was noted after HYP-PDT. In the case of SW620 cells, after HYP-PDT: no effect on GM-CSF secretion was noted; it inhibited the secretion of VCAM-1 and MIF and increased the secretion of ICAM-1. Conclusion. Photodynamic therapy with hypericin shows immunomodulatory potential in an in vitro cell line experiments. This may indicate its possible ability to modify the course of malignant tumors and therefore requires further research.
Źródło:
European Journal of Clinical and Experimental Medicine; 2023, 2; 202-216
2544-2406
2544-1361
Pojawia się w:
European Journal of Clinical and Experimental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-4 z 4

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies